Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: A study of prognosis, quality of life, and preferences for decision making

Journal of Clinical Oncology

Volumn 25, Issue 5, 2007, Pages 548-554

  Hlubocky, Fay J ^a   Ratain, Mark J ^a   Wen, Ming ^a   Daugherty, Christopher K ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CYANOCOBALAMIN; GINSENG EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; MAGNESIUM; RETINOL; SELENIUM; VITAMIN; VITAMIN D; ANTINEOPLASTIC AGENT; PLANT MEDICINAL PRODUCT;

ADULT; ADVANCED CANCER; AGED; ALTERNATIVE MEDICINE; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HYPERICUM PERFORATUM; MAJOR CLINICAL STUDY; MALE; MEDITATION; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UNIVARIATE ANALYSIS; ATTITUDE TO HEALTH; DECISION MAKING; DIET SUPPLEMENTATION; HERB DRUG INTERACTION; METHODOLOGY; MIDDLE AGED; NEOPLASM; PATIENT; PATIENT PARTICIPATION; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ATTITUDE TO HEALTH; CHICAGO; CLINICAL TRIALS, PHASE I; COMPLEMENTARY THERAPIES; DECISION MAKING; DIETARY SUPPLEMENTS; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT PARTICIPATION; PATIENTS; PLANT PREPARATIONS; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; VITAMINS;

EID: 33947505554     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.9800     Document Type: Article

References (73)

1. National Center for Complementary and Alternative Medicine: NCCAM Facts-at-a-Glance. http://altmed.od.nih.gov/about/aboutnccam
2. Eisenberg DM, Kessler RC, Foster C, et al: Unconventional medicine in the United States: Prevalence, costs, and patterns of use. N Engl J Med 328:246-252, 1993
3. Eisenberg DM, Davis RB, Ettner SL, et al: Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 280:1569-1575, 1998
4. Astin JA: Why patients use alternative medicine. JAMA 279:1548-1553, 1998
5. Cassileth BR, Lusk EJ, Strouse TB, et al: Contemporary unorthodox treatments in cancer medicine: A study of patients, treatments, and practitioners. Ann Intern Med 101:105-112, 1984
6. Cassileth BR, Lusk EJ, Guerry D, et al: Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med 324:1180-1185, 1991
7. Begbie SD, Kerestes ZL, Bell DR: Patterns of alternative medicine use by cancer patients. Med J Aust 165:545-548, 1996
8. Ernst E, Cassileth B: The prevalence of complementary/alternative medicine in cancer: A systematic review. Cancer 83:777-782, 1998
9. Yates P, Beadle G, Clavarino A, et al: Patients with terminal cancer who use alternative therapies: Their beliefs and practices. Sociol Health Ill 15:199-216, 1993
10. Sparreboom A, Cox MC, Acharya MR, et al: Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J Clin Oncol 22:2489-2503, 2004
11. Downer SM, Cody MM, McCluskey P, et al: Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86-89, 1994
12. Crocetti E, Crotti N, Feltrin A, et al: The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer 34:324-328, 1998
13. Burnstein HJ, Gelber S, Guadagnoli E, et al: Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733-1739, 1999
14. Carlsson M, Arman M, Backman M, et al: Perceived quality of life and coping for Swedish women with breast cancer who choose complementary medicine. Cancer Nurs 24:395-401, 2001
15. Paltiel O, Avitzour M, Peretz T, et al: Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 19:2439-2448, 2001
16. Richardson MA, Sanders T, Palmer JL, et al: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505-2514, 2000
17. Yates JS, Mustian KM, Morrow GR, et al: Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13:806-811, 2005
18. Molassiotis A, Fernadez-Ortega P, Pud D, et al: Use of complementary and alternative medicine in cancer patients: A European survey. Ann Oncol 16:655-663, 2005
19. Sibbritt D, Adams J, Easthope G, et al: Complementary and alternative medicine (CAM) use among elderly Australian women who have cancer. Support Care Cancer 11:548-550, 2003
20. Risberg T, Vickers A, Bremnes RM, et al: Does use of alternative medicine predict survival from cancer? Eur J Cancer 39:372-377, 2003
21. Risberg T, Kolstad A, Cassileth BR: Use of alternative medicine among Norwegian cancer patients is associated with mental distress: A follow-up study. Acta Oncol 41:646-651, 2002
22. Stoll BA: Can unorthodox cancer therapy improve quality-of-life? Ann Oncol 4:121-123, 1993
23. Sollner W, Maislinger S, DeVries A, et al: Use of complementary and alternative medicine by cancer patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior: A survey. Cancer 89:873-880, 2000
24. Correa-Velez I, Clavarino A, Barnett AG, Eastwood H: Use of complementary and alternative medicine and quality of life: Changes at the end of life. Palliat Med 17:695-703, 2003
25. Truant T, Bottorff JL: Decision making related to complementary therapies: A process of regaining control. Patient Educ Couns 38:131-142, 1999
26. Boon H, Brown JB, Gavin A, et al: Men with prostate cancer: Making decisions about complementary/alternative medicine. Med Decis Making 23:471-479, 2003
27. Caspi O, Koithan M, Criddle MW. Alternative medicine or "alternative" patients: Qualitative study of patient-oriented decision-making processes with respect to complementary and alternative medicine. Med Dec Making 24:64-79, 2004
28. Miller DR, Anderson GT, Stark JJ, et al: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16:3649-3655, 1998
29. Ernst E: Harmless herbs? A review of the recent literature. Am J Med 104:170-178, 1998
30. Labriola D, Livingston R: Possible interactions between dietary antioxidants and chemotherapy. Oncology (Huntingt) 13:1003-1008, 1999
31. Lamson DW, Brignall MS: Antioxidants in cancer therapy: Their actions and interactions with oncologic therapies. Altern Med Rev 4:304-329, 1999
32. Cassileth BR: Evaluating complementary and alternative therapies for cancer patients. CA Cancer J Clin 49:362-375, 1999
33. Weiger WA, Smith M, Boon H, et al: Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 137:889-903, 2002
34. Ladas EJ, Kelly KM: Milk thistle: Is there a role for its use as an adjunct therapy in patients with cancer? J Altern Complement Med 9:411-416, 2003
35. De Smet PA: Herbal remedies. N Engl J Med 347:2046-2056, 2002
36. Werneke U, Earl J, Seydel C, et al: Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 90:408-413, 2004
37. Ladas EJ, Jacobson JS, Kennedy DD, et al: Antioxidants and cancer therapy: A systematic review. J Clin Oncol 22:517-528, 2004
38. Ashar B, Vargo E: Shark cartilage-induced hepatitis. Ann Intern Med 125:780-781, 1996
39. Kemp DE, Franco KN: Possible leukopenia associated with long-term use of echinacea. J Am Board Fam Pract 15:417-419, 2002
40. Budzinski JW, Foster BC, Vandenhoek S, et al: An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7:273-282, 2000
41. Tamayo C, Richardson MA, Diamond S, et al: The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac. Phytother Res 14:1-14, 2000
42. McCune JS, Hatfield AJ, Blackburn AA, et al: Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 12:454-462, 2004
43. Mathijssen RH, Verweij J, de Bruijn P, et al: Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94:1247-1249, 2002
44. Mansky PJ, Straus SE: St. John's Wort: More implications for cancer patients. J Natl Cancer Inst 94:1187-1188, 2002
45. Hammerness P, Basch E, Ulbricht C, et al: St John's wort: A systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 44:271-282, 2003
46. Beijnen JH, Schellens JH: Drug interactions in oncology. Lancet Oncol 5:489-496, 2004
47. Sparber A, Bauer L, Curt G, et al: Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 27:623-630, 2000
48. Sparber A, Jonas W, White J, et al: Cancer clinical trials and subject use of natural herbal products. Cancer Invest 18:436-439, 2000
49. Dy GK, Bekele L, Hanson LJ, et al: Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 22:4810-4815, 2004
50. Daugherty CK, Fitchett G, Murphy PE, et al: Trusting God and medicine: Spirituality in advanced cancer patients volunteering for clinical trials of experimental agents. Psychooncology 13:1-12, 2004
51. Helft PR, Hlubocky F, Wen M, et al: Associations among awareness of prognosis, hopefulness, and coping in patients with advanced cancer participating in phase I clinical trials. Support Care Cancer 11:644-651, 2003
52. Daugherty CK, Banik D, Janish L, et al: A quantitative analysis of ethical issues in experimental cancer trials: A survey interview study of 144 terminally ill advanced cancer patients. IRB 22:6-14, 2000
53. Gordon EJ, Daugherty CK: Referral and decision making among advanced cancer patients participating in phase I trials at a single institution. J Clin Ethics 12:31-38, 2001
54. Daugherty C, Ratain MJ, Grochowski E, et al: Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13:1062-1072, 1995
55. Daugherty CK, Ratain MJ, Minami H, et al: A study of cohort-specific consent and patient control in a phase I cancer trial. J Clin Oncol 16:2305-2312, 1998
56. Llewellyn-Thomas HA, McGreal MJ, Thiel EC, et al: Patients' willingness to enter clinical trials: Measuring the association with perceived benefit and preference for decision participation. Soc Sci Med 32:35-42, 1991
57. Hinton J: How reliable are relatives' retrospective reports of terminal illness? Patients' and relatives' accounts compared. Soc Sci Med 43:1229-1236, 1996
58. Cella DF, Tulsky DS, Gray G, et al: The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
59. RootsWeb: Social Security Death Index interactive search. http://ssdi.genealogy.rootsweb.com/cgi-bin/ssdi.cgi
60. Janisch L, Mick R, Schilsky RL, et al: Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 74:1965-1973, 1994
61. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005
62. Roberts TG Jr, Goulart BH, Squitieri L, et al: Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130-2140, 2004
63. Ratain MJ, Mick R, Schilsky RL, et al: Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637-1643, 1993
64. Daugherty CK: Impact of therapeutic research on informed consent and the ethics of clinical trials: A medical oncology perspective. J Clin Oncol 17:1601-1617, 1999
65. Daugherty CK: Ethical issues in the development of new agents. Invest New Drugs 17:145-153, 1999
66. Meropol NJ, Weinfurt KP, Burnett CB, et al: Perceptions of patients and physicians regarding phase I cancer clinical trials: Implications for physician-patient communication. J Clin Oncol 21:2589-2596, 2003
67. Weinfurt KP, Castel LD, Li Y, et al: The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 98:166-175, 2003
68. Shumay DM, Maskarinec G, Gotay CC, et al: Determinants of the degree of complementary and alternative medicine use among patients with cancer. J Altern Complement Med 8:661-671, 2002
69. Steel JL, Eton DT, Cella D, et al: Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol 17:304-312, 2006
70. Yost KJ, Cella D, Chawla A, et al: Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution-and anchor-based approaches. J Clin Epidemiol 58:1241-1251, 2005
71. Sloan JA, Cella D, Hays RD: Clinical significance of patient-reported questionnaire data: Another step toward consensus. J Clin Epidemiol 58:1217-1219, 2005
72. Cella D, Eton DT, Fairclough DL, et al: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 55:285-295, 2002
73. Yost KJ, Eton DT: Combining distribution-and anchor-based approaches to determine minimally important differences: The FACIT Experience. Eval Health Profess 28:172-191, 2005